213 related articles for article (PubMed ID: 25381015)
1. Intralesional therapy for metastatic melanoma.
Sloot S; Rashid OM; Zager JS
Expert Opin Pharmacother; 2014 Dec; 15(18):2629-39. PubMed ID: 25381015
[TBL] [Abstract][Full Text] [Related]
2. Intralesional therapy as a treatment for locoregionally metastatic melanoma.
Miura JT; Zager JS
Expert Rev Anticancer Ther; 2018 Apr; 18(4):399-408. PubMed ID: 29466885
[TBL] [Abstract][Full Text] [Related]
3. Intralesional immunotherapy as a strategy to treat melanoma.
Nouri N; Garbe C
Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
[TBL] [Abstract][Full Text] [Related]
4. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
5. Regional therapies for locoregionally advanced and unresectable melanoma.
Weitman ES; Zager JS
Clin Exp Metastasis; 2018 Aug; 35(5-6):495-502. PubMed ID: 29736626
[TBL] [Abstract][Full Text] [Related]
6. Developments in Intralesional Therapy for Metastatic Melanoma.
Sloot S; Rashid OM; Sarnaik AA; Zager JS
Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
[TBL] [Abstract][Full Text] [Related]
7. Management of Locoregionally Advanced Melanoma.
Pointer DT; Zager JS
Surg Clin North Am; 2020 Feb; 100(1):109-125. PubMed ID: 31753106
[TBL] [Abstract][Full Text] [Related]
8. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma.
Beasley GM; Zager JS; Thompson JF
Ann Surg Oncol; 2020 Jan; 27(1):35-42. PubMed ID: 31471842
[TBL] [Abstract][Full Text] [Related]
9. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?
Testori A; Intelisano A; Verrecchia F; Menicanti C; Tosti G; Grassi E; Pari C; Pennacchioli E
Dermatol Ther; 2012; 25(5):443-51. PubMed ID: 23046023
[TBL] [Abstract][Full Text] [Related]
10. Locoregional therapies in melanoma.
Abbott AM; Zager JS
Surg Clin North Am; 2014 Oct; 94(5):1003-15, viii. PubMed ID: 25245964
[TBL] [Abstract][Full Text] [Related]
11. Electrochemotherapy for the Treatment of Unresectable Locoregionally Advanced Cutaneous Melanoma: A Systematic Review.
Aguado-Romeo MJ; Benot-López S; Romero-Tabares A
Actas Dermosifiliogr; 2017 Mar; 108(2):91-97. PubMed ID: 27769538
[TBL] [Abstract][Full Text] [Related]
12. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
[TBL] [Abstract][Full Text] [Related]
13. The use of electrochemotherapy in combination with immunotherapy in the treatment of metastatic melanoma: a focused review.
Goggins CA; Khachemoune A
Int J Dermatol; 2019 Aug; 58(8):865-870. PubMed ID: 30479009
[TBL] [Abstract][Full Text] [Related]
14. Local and intralesional therapy of in-transit melanoma metastases.
Testori A; Faries MB; Thompson JF; Pennacchioli E; Deroose JP; van Geel AN; Verhoef C; Verrecchia F; Soteldo J
J Surg Oncol; 2011 Sep; 104(4):391-6. PubMed ID: 21858834
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma.
Gaudy C; Richard MA; Folchetti G; Bonerandi JJ; Grob JJ
J Cutan Med Surg; 2006; 10(3):115-21. PubMed ID: 17241586
[TBL] [Abstract][Full Text] [Related]
16. A safety review of recently approved and late-stage trial treatments for metastatic melanoma: systemic and regional therapies.
Perez MC; Depalo DK; Zager JS
Expert Opin Drug Saf; 2023; 22(9):789-797. PubMed ID: 37551723
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
Thompson JF; Agarwala SS; Smithers BM; Ross MI; Scoggins CR; Coventry BJ; Neuhaus SJ; Minor DR; Singer JM; Wachter EA
Ann Surg Oncol; 2015 Jul; 22(7):2135-42. PubMed ID: 25348780
[TBL] [Abstract][Full Text] [Related]
18. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.
Möller MG; Salwa S; Soden DM; O'Sullivan GC
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1611-30. PubMed ID: 19895245
[TBL] [Abstract][Full Text] [Related]
19. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
20. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
